PER-020-02已完成未知
MULTICENTRIC STUDY DOUBLE BLIND, RANDOMIZED, PARALLEL, CONTROLLED WITH PLACEBO AND ACTIVE CONTROLLER TO EVALUATE THE EFFECTIVENESS AND SAFETY OF L-410198 IN THE ALTERATION OF LIPIDS IN PATIENTS THAT SUFFER FROM METABOLIC SYNDROME AND DYSLIPIDEMIAS
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2002年2月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •* Between 21 and 65 years of age, inclusive.
- •* Fasting triglyceride levels of> 180 mg / dL (> 2.0 mmol / L), but <600 mg / dL (<6.8 mmol / L).
- •* Have at least 2 of the following additional Metabolic Syndrome criteria (as defined by NCEP)
排除标准
- •It excludes participation in the study of those individuals who fail to comply with
- •one of the criteria of the visit 1
研究者
相似试验
已完成
不适用
TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES WITH AN INVESTIGATIONAL NEW DRUGPER-084-02GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,
已完成
不适用
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, IN PARALLEL GROUPS, WITH ACTIVE CONTROL, OF 24 WEEKS OF DURATION, TO EVALUATE THE EFFICACY OF THE COMBINATION VALSARTAN / HYDROCHLOROTHYAZIDE VERSUS AMLODIPINE ON THE SYSTOLIC ARTERIAL PRESSURE IN PATIENTS WITH MODERATE HYPERTENSION WITH RISK FACTORS AND / OR CARDIOVASCULAR CONCOMYANT DISEASE-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-010-03OVARTIS BIOSCIENSES PERU S.A.,
已完成
1 期
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, WITH ACTIVE CONTROL, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY AND SAFETY OF VALSARTAN 320 MG COMPARED WITH VALSARTAN 160 MG IN HYPERTENSION PATIENTS-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-060-03OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
Estudio de Tamiflu vs placebo en el tratamiento profiláctico de la gripe en pacientes inmunocomprometidosProfilaxis estacional de la gripe en pacientes inmunocomprometidosMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2006-002473-47-ESF.Hoffmann-La Roche Ltd.470
进行中（未招募）
1 期
Estudio multicéntrico, doble ciego, randomizado, de 12 meses de duración, controlado con placebo, para evaluar el efecto hipolipemiante, la seguridad y la tolerabilidad de AVE5530 25 mg/día y 50mg/día en tratamiento concomitante con estatinas (inhibidores de la HMG-CoA reductasa) en pacientes con hipercolesterolemia primariaA multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.Hipercolesterolemia primariaPrimary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-001550-41-ESSanofi-Aventis Recherche & Développement1,000